1 / 17

ATRIAL FIBRILLATION

ATRIAL FIBRILLATION. NILOFAR RAHMAN, MD AMIT KUMAR, MD. DEFINITION A SVT with uncoordinated atrial activation with constant deterioration of atrial mechanical function

marijke-nika
Download Presentation

ATRIAL FIBRILLATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ATRIAL FIBRILLATION NILOFAR RAHMAN, MD AMIT KUMAR, MD

  2. DEFINITION • A SVT with uncoordinated atrial activation with constant deterioration of atrial mechanical function • On EKGs it is defined by replacement of consistent P waves with rapid oscillations that vary in size, shape and timing ass. With an irregular RVR when AV conduction is intact.

  3. EPIDEMIOLOGY

  4. CLASSIFICATION • PAROXYSMAL:Self terminates< 7 days, usu, within 24 hrs. • PERSISTENT: > 7 days, terminate spontaneously or by cardioversion • PERMANENT: > 1 YR, CV attempted or failed • LONE: Without any structural heart disease

  5. ASSOCIATED DISEASES • HTN: 1.4 fold increase risk • CHD: when complicated by acute MI or heart failure • CASS trial: RR was 1.98 in 7 yrs • VALVULAR HEART DISEASE: • MS, MR, TR: 70% RISK • MS, MR: 52% • ISOLATED MS: 29% • HYPERTROPHIC CMP: • CONGENITAL HEART DISEASE • OTHERS: hyperthyroidism, PE, COPD, lupus myocarditis • OSA: reduced reccurence with treatment

  6. CLINICAL MANIFESTATIONS • SYMPTOMATIC OR ASX EVEN IN SAME PT. • PALPITATION/CP/DYSPNEA/FATIGUE/LIGHTHEADEDNESS/SYNCOPE • EMBOLIC COMPLIC. OR HEART FAILURE • POLYURIA: ANP • ASS. RVR- CMP

  7. EVALUATION • H&P: • EKG: verify AF • CXR: lungs, vasculature and cardiac outline • ECHO • TTE: size and function of chambers, valvular heart diseases • TEE: thrombi in left atrium • TSH • ADDITIONAL TESTING: • EXERCISE TEST • HOLTER/EVENT MONITOR

  8. GENERAL PRINCIPLES OF TREATMENT

  9. RATE VS. RHYTHM CONTROL • AFFIRM AND RACE TRIALS: 2 CONCLUSIONS- • Embolic event occur in equal frequency • lower incidence of primary end point with rate control strategy

  10. TREATMENT • RATE CONTROL • Beta blockers • Calcium channel blockers • Digoxin • GOALS: HR<80 bpm, 24 hr. Holter average <100 bpm, HR < 110 bpm in 6 min. walk • Non pharmacologic method: radiofrequency ablation and pacemaker implantation

  11. RHYTHM CONTROL • PHARMACOLOGIC • DIRECT CURRENT CARDIOVERSION • Anticoagulation for 3-4 weeks before CV • Anticoag for 1 month after CV • usu done in hemodynamically unstable pts. • success rate is 75-93%, inversely related to atrial size and duration

  12. …contd. RHYTHM CONTROL • Maintenance of NSR: • 20-30% maintain NSR > 1 yr. w/o antiarrythmics • duration of <1 yr, atrial size < 4 cm. • reversible causes • Amiodaroneis known to be most effective • CTAF and AFFIRM trials • Flecainide and propefenone in those without heart disease

  13. ANTICOAGULATION IN AF • RISK OF STROKE IS 3-5% WITHOUT ANTICOAGULATION • CHADS2 SCORE • SCORE OF 0: ASA • SCORE 1-2: ASA/WARFARIN • SCORE > 2: WARFARIN, INR GOAL 2-3

  14. DABIGATRAN • APPROVED IN 10/10 • RE-LY TRIAL EVALUATED SAFETY OF 2 DOSES • RESULTS: • Rate of stroke was lesser • High dose - more effective than warfarin • Risk of bleeding was lesser in low dose • All-cause mortality was reduced

  15. DISADVANTAGES • Twice dosing • High cost • Lack of an antidote • Dose adjustment for those with CKD • lack of long term safety data

  16. THANK YOU

More Related